Article ; Online: DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
2024 Volume 43, Issue 19, Page(s) 1399–1410
Abstract: Castration-resistant prostate cancer (CRPC) is an aggressive disease with poor prognosis, and there is an urgent need for more effective therapeutic targets to address this challenge. Here, we showed that dihydroorotate dehydrogenase (DHODH), an enzyme ... ...
Abstract | Castration-resistant prostate cancer (CRPC) is an aggressive disease with poor prognosis, and there is an urgent need for more effective therapeutic targets to address this challenge. Here, we showed that dihydroorotate dehydrogenase (DHODH), an enzyme crucial in the pyrimidine biosynthesis pathway, is a promising therapeutic target for CRPC. The transcript levels of DHODH were significantly elevated in prostate tumors and were negatively correlated with the prognosis of patients with prostate cancer. DHODH inhibition effectively suppressed CRPC progression by blocking cell cycle progression and inducing apoptosis. Notably, treatment with DHODH inhibitor BAY2402234 activated androgen biosynthesis signaling in CRPC cells. However, the combination treatment with BAY2402234 and abiraterone decreased intratumoral testosterone levels and induced apoptosis, which inhibited the growth of CWR22Rv1 xenograft tumors and patient-derived xenograft organoids. Taken together, these results establish DHODH as a key player in CRPC and as a potential therapeutic target for advanced prostate cancer. |
---|---|
MeSH term(s) | Male ; Humans ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Prostatic Neoplasms, Castration-Resistant/pathology ; Prostatic Neoplasms, Castration-Resistant/metabolism ; Dihydroorotate Dehydrogenase ; Animals ; Oxidoreductases Acting on CH-CH Group Donors/antagonists & inhibitors ; Mice ; Androstenes/pharmacology ; Androstenes/therapeutic use ; Cell Line, Tumor ; Xenograft Model Antitumor Assays ; Apoptosis/drug effects ; Cell Proliferation/drug effects |
Chemical Substances | Dihydroorotate Dehydrogenase ; Oxidoreductases Acting on CH-CH Group Donors (EC 1.3.-) ; abiraterone (G819A456D0) ; Androstenes |
Language | English |
Publishing date | 2024-03-13 |
Publishing country | England |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 639046-8 |
ISSN | 1476-5594 ; 0950-9232 |
ISSN (online) | 1476-5594 |
ISSN | 0950-9232 |
DOI | 10.1038/s41388-024-03005-4 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 2218: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.